Institut National D'Oncologie
About Institut National D'Oncologie
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
6
Institut National d'Oncologie, Morocco
2
International Atomic Energy Agency
2
Pfizer
2
Gustave Roussy, Cancer Campus, Grand Paris
1
Millennium Pharmaceuticals, Inc.
1
Clinical Trials at Institut National D'Oncologie
During the past decade, Institut National D'Oncologie conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 4 clinical trials were completed, i.e. on
average, 57.1% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer
1995-02-01
Completed
3,300
CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy
2005-11-01
2010-06-01
Completed
601
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
2008-05-01
2017-06-17
Completed
487
Resource-sparing Post-mastectomy Radiotherapy in Breast Cancer
2007-03-01
2012-12-01
Unknown status
600
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
2012-05-17
2020-02-19
Completed
2,577
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
2012-06-01
2019-09-20
Completed
1,436
A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
2014-02-21
2018-11-25
Completed
174
Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
2015-01-21
2018-02-11
Completed
449
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Institut National D'Oncologie" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Institut National d'Oncologie, Morocco" with 2 trials
sponsored, "International Atomic Energy Agency" with 2 trials sponsored, "Pfizer" with 2 trials sponsored and "Gustave Roussy, Cancer Campus, Grand Paris"
with 2 trials sponsored. Other sponsors include -4 different institutions and
companies that sponsored additional 6 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Institut National D'Oncologie"
#1 collaborator was "International Network for Cancer Treatment and Research" with 1 trials as a collaborator and "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Institut National D'Oncologie
According to Clinical.Site data, the most researched conditions in "Institut National D'Oncologie" are
"Breast Cancer" (2 trials), "Breast Neoplasms" (2 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Cervix Cancer" (1 trials) and "Colon Adenocarcinoma" (1 trials). Many other conditions were trialed in "Institut National D'Oncologie" in a lesser frequency.
Clinical Trials Intervention Types at Institut National D'Oncologie
Most popular intervention types in "Institut National D'Oncologie" are "Drug" (9 trials), "Radiation" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.
The name of intervention was led by "Paclitaxel" (3 trials), "Atezolizumab" (2 trials), "Carboplatin" (2 trials), "Docetaxel" (2 trials) and "Radiotherapy" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Institut National D'Oncologie
The vast majority of trials in "Institut National D'Oncologie" are
12 trials for "All" genders and 2 trials for "Female" genders.
Clinical Trials Status at Institut National D'Oncologie
Currently, there are NaN active trials in "Institut National D'Oncologie".
undefined are not yet recruiting,
1 are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 11 completed trials in Institut National D'Oncologie,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Institut National D'Oncologie, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 9 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".